london-biotech
(3)
Baseimmune
Baseimmune is a London-based biotech that uses a proprietary deep-learning platform to design synthetic antigens - the active ingredients in vaccines and immunotherapies. Founded in 2019 by three researchers who met at Oxford's Jenner Institute, the company originally built AI-designed 'future-proof' vaccine candidates against fast-mutating pathogens such as coronavirus, malaria and African swine fever. In 2026 it extended its computational antigen-design platform beyond infectious disease into chronic conditions, with a lead program targeting idiopathic pulmonary fibrosis. Baseimmune closed an $11.3M (about GBP 9M) Series A in February 2024 led by MSD Global Health Innovation Fund and IQ Capital.
Leucid Bio
Leucid Bio is a clinical-stage London biotech developing next-generation CAR-T cell therapies for refractory solid tumors. Spun out of King's College London in 2014 to commercialize two decades of research by Dr John Maher, the company's proprietary Lateral CAR platform redesigns the CAR receptor so its signalling domains sit laterally alongside the cell membrane - mimicking natural immune receptors to boost potency while reducing toxicity. Its lead candidate, LEU011, is an autologous NKG2D-targeting CAR-T therapy now in the Phase I/IIa AERIAL trial for refractory solid tumors.
Myricx Bio
Myricx Bio is a London-based oncology biotech developing a completely new class of payloads for antibody-drug conjugates (ADCs), built on inhibitors of N-myristoyltransferase (NMT). Spun out of Imperial College London and the Francis Crick Institute, the company aims to give ADCs a fresh way to kill cancer cells that resist today's standard payloads. In July 2024 it closed a £90m ($114m) Series A, one of Europe's largest biotech rounds that year, to push its NMTi-ADC pipeline toward clinical trials.